Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations

2025/02/12 by Adel Shahnam, Alexander Davis, Lauren Julia Brown +27 · 1 voice
Biochemistry, Genetics and Molecular Biology · Medicine · #Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis #Lung Cancer Treatments and Mutations #Melanoma and MAPK Pathways

paper · doi:10.1016/j.lungcan.2025.108421

openalex publication_date 2025/02/12 · crossref created 2025/02/12 · crossref issued 2025/03/01 · crossref published 2025/03/01 · crossref published-print 2025/03/01 · crossref deposited 2025/04/05 · openalex created_date 2025/10/10 · crossref indexed 2026/07/25 · openalex updated_date 2026/07/25

Citations

• Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment

Discussions

• KRAS G12C mutations in non-small cell lung cancer (NSCLC) have been associated with improved immune-checkpoint inhibition (ICI) outcomes. doi.org/10.1016/j.lu... [bsky, 0 points, 1 comments]